# Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

> **NCT03334500** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** [18F]FluorThanatrace
- **DRUG:** Poly(ADP Ribose) Polymerase 1

## Key facts

- **NCT ID:** NCT03334500
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-14
- **Primary completion:** 2027-02-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334500, "Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT03334500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*